Aevitas Wealth Management’s NovoCure NVCR Stock Holding History

Aevitas Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-500	Closed	-$24K	–	255
2019 Q1	$24K	Hold	500	–	–	0.02%	244
2018 Q4	$17K	Hold	500	–	–	0.02%	261
2018 Q3	$26K	Hold	500	–	–	0.02%	261
2018 Q2	$16K	Hold	500	–	–	0.02%	296
2018 Q1	$11K	Hold	500	–	–	0.01%	309
2017 Q4	$10K	Buy	+500	New	+$9.63K	0.01%	319

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Aevitas Wealth Management's NVCR Position: Q2 2019 in Review

Aevitas Wealth Management sold out of NovoCure (NVCR) in Q2 2019, closing a stake of 500 shares — an estimated $24K sold.

Aevitas Wealth Management first reported a position in NVCR in Q4 2017 and held it in 6 quarters. The position peaked at $26K in Q3 2018. 197 funds tracked by Wall St. Rank hold NVCR as of Q2 2019.

Aevitas Wealth Management reported no remaining NovoCure position as of Q2 2019 after selling out during the quarter.
Aevitas Wealth Management sold 500 NovoCure shares in Q2 2019, an estimated $24K.
Aevitas Wealth Management first reported a position in NovoCure in Q4 2017 and held it in 6 quarters.
Aevitas Wealth Management's NovoCure position peaked at $26K in Q3 2018.
197 funds tracked by Wall St. Rank held NovoCure as of Q2 2019.

Based on Aevitas Wealth Management's 13F filing for Q2 2019, filed 26 Jul 2019.